Literature DB >> 34091877

Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients.

Taku Nose1, Yoshinori Imamura2, Shinya Ohata1, Shiro Kimbara1, Yoshiharu Miyata1, Yasuko Hyogo1, Yoshimi Fujishima1, Yohei Funakoshi1, Masanori Toyoda1, Naomi Kiyota1,3, Hironobu Minami1,3.   

Abstract

BACKGROUND: The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated. METHODS AND
RESULTS: Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic.
CONCLUSIONS: In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.

Entities:  

Keywords:  Cancer-associated venous thromboembolism; Incidence; Solid malignancy; Venous thromboembolism

Year:  2021        PMID: 34091877     DOI: 10.1007/s12185-021-03167-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; N A Patwardhan; B Jovanovic; A Forcier; J E Dalen
Journal:  Arch Intern Med       Date:  1991-05

2.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Authors:  Helen K Chew; Theodore Wun; Danielle Harvey; Hong Zhou; Richard H White
Journal:  Arch Intern Med       Date:  2006-02-27

3.  Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer.

Authors:  Laurel A Menapace; Derick R Peterson; Andrea Berry; Tarek Sousou; Alok A Khorana
Journal:  Thromb Haemost       Date:  2011-06-28       Impact factor: 5.249

4.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

5.  Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone.

Authors:  Masahito Sakuma; Mashio Nakamura; Norikazu Yamada; Satoshi Ota; Kunio Shirato; Takeshi Nakano; Masaaki Ito; Takao Kobayashi
Journal:  Circ J       Date:  2008-12-18       Impact factor: 2.993

6.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Nigel S Key; Alok A Khorana; Nicole M Kuderer; Kari Bohlke; Agnes Y Y Lee; Juan I Arcelus; Sandra L Wong; Edward P Balaban; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Mark N Levine; Howard A Liebman; Margaret A Tempero; Gary H Lyman; Anna Falanga
Journal:  J Clin Oncol       Date:  2019-08-05       Impact factor: 44.544

8.  Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Authors:  Alok A Khorana; Gerald A Soff; Ajay K Kakkar; Saroj Vadhan-Raj; Hanno Riess; Ted Wun; Michael B Streiff; David A Garcia; Howard A Liebman; Chandra P Belani; Eileen M O'Reilly; Jai N Patel; Habte A Yimer; Peter Wildgoose; Paul Burton; Ujjwala Vijapurkar; Simrati Kaul; John Eikelboom; Robert McBane; Kenneth A Bauer; Nicole M Kuderer; Gary H Lyman
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 176.079

9.  Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study.

Authors:  Hiromitsu Kitayama; Tomohiro Kondo; Junko Sugiyama; Kazutomo Kurimoto; Yasuhiro Nishino; Michiaki Hirayama; Yasushi Tsuji
Journal:  BMC Cancer       Date:  2017-05-19       Impact factor: 4.430

10.  Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival.

Authors:  T Gary; K Belaj; K Steidl; M Pichler; F Eisner; H Stöger; F Hafner; H Froehlich; H Samonigg; E Pilger; M Brodmann
Journal:  Br J Cancer       Date:  2012-09-11       Impact factor: 7.640

View more
  1 in total

1.  Occult Non-Small Cell Lung Cancer: An Underappreciated Disease.

Authors:  Jingsheng Cai; Fan Yang; Xun Wang
Journal:  J Clin Med       Date:  2022-03-03       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.